Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 26 | 2023 | 1407 | 5.730 |
Why?
|
| Proton Therapy | 13 | 2023 | 151 | 4.670 |
Why?
|
| Survivors | 15 | 2022 | 359 | 3.760 |
Why?
|
| Cancer Survivors | 8 | 2023 | 247 | 2.890 |
Why?
|
| Cerebellar Neoplasms | 6 | 2024 | 460 | 2.470 |
Why?
|
| Craniospinal Irradiation | 6 | 2023 | 66 | 2.350 |
Why?
|
| Medulloblastoma | 5 | 2024 | 569 | 2.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2021 | 808 | 2.060 |
Why?
|
| Cognition | 8 | 2023 | 814 | 1.790 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 449 | 1.720 |
Why?
|
| Mutism | 2 | 2024 | 32 | 1.610 |
Why?
|
| Intelligence | 6 | 2023 | 107 | 1.440 |
Why?
|
| Photons | 3 | 2021 | 53 | 1.290 |
Why?
|
| Cognition Disorders | 5 | 2019 | 579 | 1.250 |
Why?
|
| Child | 43 | 2024 | 25768 | 1.030 |
Why?
|
| Protons | 6 | 2023 | 98 | 0.980 |
Why?
|
| Executive Function | 3 | 2021 | 124 | 0.970 |
Why?
|
| Survivorship | 2 | 2023 | 44 | 0.960 |
Why?
|
| Neurocognitive Disorders | 3 | 2021 | 77 | 0.940 |
Why?
|
| Attention | 4 | 2017 | 201 | 0.930 |
Why?
|
| Craniopharyngioma | 2 | 2023 | 35 | 0.910 |
Why?
|
| Pituitary Neoplasms | 2 | 2023 | 85 | 0.860 |
Why?
|
| Intelligence Tests | 3 | 2022 | 63 | 0.850 |
Why?
|
| Adolescent | 29 | 2024 | 20525 | 0.810 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2016 | 237 | 0.800 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 81 | 0.720 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 148 | 0.690 |
Why?
|
| Language Development Disorders | 1 | 2022 | 179 | 0.690 |
Why?
|
| Neuropsychological Tests | 10 | 2024 | 987 | 0.690 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 314 | 0.680 |
Why?
|
| Male | 36 | 2024 | 65867 | 0.580 |
Why?
|
| Cisplatin | 1 | 2019 | 287 | 0.570 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 157 | 0.570 |
Why?
|
| Social Class | 1 | 2019 | 205 | 0.570 |
Why?
|
| Medical Oncology | 4 | 2024 | 245 | 0.550 |
Why?
|
| Female | 36 | 2024 | 71617 | 0.550 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 431 | 0.540 |
Why?
|
| Child, Preschool | 13 | 2024 | 14806 | 0.530 |
Why?
|
| Aptitude | 1 | 2016 | 12 | 0.510 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 317 | 0.510 |
Why?
|
| Smoking | 3 | 2011 | 1136 | 0.510 |
Why?
|
| Humans | 50 | 2024 | 133736 | 0.510 |
Why?
|
| Social Adjustment | 3 | 2022 | 79 | 0.500 |
Why?
|
| Child Development | 1 | 2016 | 286 | 0.430 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 850 | 0.410 |
Why?
|
| Smoking Prevention | 1 | 2011 | 38 | 0.360 |
Why?
|
| Mentors | 3 | 2023 | 161 | 0.350 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1496 | 0.350 |
Why?
|
| Neoplasms | 5 | 2023 | 3029 | 0.350 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 3992 | 0.330 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2023 | 217 | 0.330 |
Why?
|
| Intention | 1 | 2010 | 97 | 0.330 |
Why?
|
| Aggression | 1 | 2010 | 231 | 0.290 |
Why?
|
| Feeding Behavior | 1 | 2014 | 731 | 0.280 |
Why?
|
| Quality of Life | 3 | 2023 | 2150 | 0.280 |
Why?
|
| Body Mass Index | 1 | 2014 | 1715 | 0.270 |
Why?
|
| Mentoring | 2 | 2019 | 82 | 0.270 |
Why?
|
| Radiation Injuries | 2 | 2019 | 166 | 0.270 |
Why?
|
| Brain | 3 | 2023 | 3226 | 0.270 |
Why?
|
| Prognosis | 4 | 2020 | 5073 | 0.260 |
Why?
|
| Emotions | 2 | 2024 | 364 | 0.260 |
Why?
|
| Glioma | 2 | 2021 | 538 | 0.250 |
Why?
|
| Young Adult | 8 | 2023 | 9874 | 0.250 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5468 | 0.240 |
Why?
|
| Wechsler Scales | 2 | 2016 | 20 | 0.230 |
Why?
|
| Adult | 11 | 2024 | 31880 | 0.200 |
Why?
|
| Nursing | 1 | 2002 | 11 | 0.200 |
Why?
|
| Nurse-Patient Relations | 1 | 2002 | 17 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 168 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 57 | 0.190 |
Why?
|
| Patient Preference | 1 | 2023 | 135 | 0.190 |
Why?
|
| Infant | 5 | 2023 | 13174 | 0.180 |
Why?
|
| Perception | 1 | 2002 | 236 | 0.180 |
Why?
|
| Parents | 4 | 2023 | 1064 | 0.170 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3167 | 0.170 |
Why?
|
| Neuropsychology | 1 | 2020 | 22 | 0.170 |
Why?
|
| Research | 1 | 2022 | 273 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 187 | 0.160 |
Why?
|
| Program Evaluation | 2 | 2019 | 455 | 0.160 |
Why?
|
| Syndrome | 1 | 2022 | 1159 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2020 | 5195 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 207 | 0.150 |
Why?
|
| Transition to Adult Care | 1 | 2020 | 119 | 0.150 |
Why?
|
| Caregivers | 1 | 2023 | 586 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 292 | 0.140 |
Why?
|
| Oncologists | 1 | 2017 | 31 | 0.140 |
Why?
|
| Pediatricians | 1 | 2017 | 71 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1850 | 0.130 |
Why?
|
| School Teachers | 1 | 2016 | 8 | 0.130 |
Why?
|
| Fatigue | 3 | 2022 | 203 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1309 | 0.120 |
Why?
|
| Sample Size | 1 | 2016 | 88 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2023 | 13005 | 0.120 |
Why?
|
| Reaction Time | 1 | 2016 | 181 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 313 | 0.120 |
Why?
|
| Bereavement | 1 | 2005 | 20 | 0.120 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 97 | 0.110 |
Why?
|
| Linear Models | 1 | 2016 | 723 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2023 | 17423 | 0.110 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 106 | 0.100 |
Why?
|
| Terminal Care | 1 | 2005 | 120 | 0.100 |
Why?
|
| Self Report | 1 | 2016 | 553 | 0.100 |
Why?
|
| Clinical Nursing Research | 1 | 2002 | 5 | 0.100 |
Why?
|
| Nursing Assessment | 1 | 2002 | 24 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 920 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2013 | 148 | 0.100 |
Why?
|
| Behavioral Symptoms | 1 | 2012 | 25 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 6591 | 0.090 |
Why?
|
| Family | 1 | 2005 | 589 | 0.090 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 72 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2005 | 421 | 0.090 |
Why?
|
| Age Factors | 2 | 2021 | 2990 | 0.090 |
Why?
|
| Risk Factors | 3 | 2017 | 11114 | 0.090 |
Why?
|
| Divorce | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3743 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2010 | 58 | 0.090 |
Why?
|
| Palliative Care | 1 | 2005 | 461 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2012 | 183 | 0.090 |
Why?
|
| Social Behavior | 1 | 2012 | 230 | 0.080 |
Why?
|
| Canada | 1 | 2011 | 347 | 0.080 |
Why?
|
| Health Surveys | 1 | 2011 | 262 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 130 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1386 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2012 | 571 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1492 | 0.070 |
Why?
|
| Logistic Models | 1 | 2010 | 1908 | 0.060 |
Why?
|
| United States | 2 | 2011 | 11711 | 0.060 |
Why?
|
| Communication | 2 | 2005 | 546 | 0.060 |
Why?
|
| Research Personnel | 1 | 2024 | 135 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2023 | 231 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 162 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2022 | 72 | 0.050 |
Why?
|
| Time Factors | 1 | 2013 | 6585 | 0.050 |
Why?
|
| Pediatrics | 2 | 2024 | 1218 | 0.050 |
Why?
|
| Focus Groups | 1 | 2002 | 212 | 0.050 |
Why?
|
| Middle Aged | 3 | 2023 | 29298 | 0.040 |
Why?
|
| Telomerase | 1 | 2021 | 179 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 72 | 0.040 |
Why?
|
| Health Personnel | 1 | 2024 | 543 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2020 | 145 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 370 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 897 | 0.040 |
Why?
|
| DNA Repair | 1 | 2021 | 632 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1487 | 0.030 |
Why?
|
| Career Mobility | 1 | 2017 | 54 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 105 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1191 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 456 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1470 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1868 | 0.030 |
Why?
|
| Texas | 1 | 2023 | 3703 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1339 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 3479 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 972 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 239 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 7196 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3430 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2002 | 368 | 0.020 |
Why?
|
| Faculty | 1 | 2010 | 109 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2005 | 601 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 298 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 700 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2239 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 3031 | 0.010 |
Why?
|
| Aged | 1 | 2002 | 21680 | 0.010 |
Why?
|